The medical device space is growing rapidly as new startups and investments from major players enter the market. Some of the most notable investors in medical devices include venture capital firms such as Kleiner Perkins Caufield & Byers, Sequoia Capital, and Accel Partners, as well as large companies such as Johnson & Johnson and Medtronic.
This influx of investment is driving innovation in the medical device space, with new devices and treatments being developed all the time. This growth is also creating opportunities for entrepreneurs, who can now launch their own medical device startups and access funding from major players.
Implementing child-resistant and senior-friendly blister packaging is essential for pharmacies to enhance safety and accessibility. Such packaging significantly reduces the risk of accidental poisoning among children by making it difficult for them to open, while remaining easy for seniors to use.
Indero is a dual-focus CRO for dermatology and rheumatology, with over 25 years of experience in clinical research and trial delivery.
Isa Rizk, Co-Founder and CEO of Reflow Medical. “This presence allows us to better address the needs of international markets by providing direct sales solutions and forming key distribution collaborations. Our goal is to deliver breakthrough technologies that support physicians and improve patient outcomes worldwide.”
Aletta is the first and only Autonomous Robotic Phlebotomy Device™ (ARPD™), a unique technology descriptor that establishes a new category of medical robotics dedicated to optimizing blood collection. As the exclusive ARPD™, Aletta sets the global industry standard for automated venous blood draws—enhancing clinical precision, safety, efficiency, and patient experience.
Patients use Pylo remote monitoring devices to collect and securely transmit health data like blood pressure, weight, blood glucose, oxygen saturation, and pulse rate readings to their care teams. With this data, providers can identify potential health issues early and intervene promptly, preventing potential hospitalizations.
“We are pleased to see these latest patent issuances that protect PathMaker’s novel technology for the non-invasive treatment of ALS,” said Jake Maslow, J.D., Co-Founder and Chief Intellectual Property Officer at PathMaker. “These patents provide additional protection specific to the treatment of ALS that goes beyond the more than 40 issued patents we already have protecting our platform globally.”